The Medical Developments International Ltd (ASX: MVP) share price will be on watch this morning follow a positive announcement relating to its Penthrox product.
What is Penthrox?
Penthrox, or the green whistle, is a fast onset, non-opioid analgesic. It is indicated for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures.
It has been used safely and effectively for over 40 years in Australia with more than 5 million units sold.
In recent times the company has been looking at expanding its use, hence today’s announcement.
What did Medical Developments International announce?
This morning the healthcare company announced that data across 11 abstracts of studies conducted throughout Europe have demonstrated multiple positive results of Penthrox.
This includes Penthrox demonstrating superiority over intravenous (IV) morphine, paracetamol, ketoprofen, and NSAIDS within a trauma setting.
It also found that Penthrox added to the standard of care (SoC) demonstrates superiority over SoC plus a placebo within a trauma setting.
The product was also successful in dislocation injuries. Its use resulted in reduced time spent in the Emergency Departments, which improves the patient experience and reduces crowding.
The release explains that other studies confirmed previously published data. This includes Penthrox being an efficacious, well tolerated/safe and rapidly acting analgesic in trauma settings.
Another positive was that the studies commonly reported that Penthrox exceeded patient/clinician expectations and/or resulted in a high degree of treatment satisfaction from patients and health care professionals.
The company’s CEO, John Sharman, was delighted with the study results.
He said: “We are delighted with the results of these recent European clinical trials demonstrating superiority of Penthrox over Standard of Care treatments (intravenous (IV) morphine, IV paracetamol, ketoprofen or NSAIDS) within the acute trauma setting. This reinforces the global potential for Penthrox as a simple, fast and effective non-opioid pain medication.”
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of June 30th
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Medical Developments International Limited. The Motley Fool Australia has recommended Medical Developments International Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
- Advance NanoTek share price on watch after mixed full year result and outlook – August 5, 2020 6:36pm
- Why I would add Coles and this ASX share to my retirement portfolio – August 5, 2020 6:00pm
- 3 top ASX shares that could be quality buy and hold options – August 5, 2020 5:00pm